Congestive heart failure · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in congestive heart failure compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Cardiovascular surgery · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in cardiovascular surgery compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Aortic root diameter > 6 cm · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in aortic root diameter > 6 cm compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at maximum · patients without heart failure
The intervention probably leads to lower all‐cause mortality at maximum (moderate certainty).
1 finding from 1 review
Intervention not reported
Major cardiovascular events (cardiovascular mortality or non‐fatal myocardial infarction) at maximum · patients without heart failure
The intervention may leads to lower major cardiovascular events (cardiovascular mortality or non‐fatal… (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events at maximum · patients without heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · patients without heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Angina pectoris at maximum · patients without heart failure
The intervention showed no clear difference in angina pectoris at maximum (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality at maximum · patients without heart failure
The intervention may leads to lower cardiovascular mortality at maximum (low certainty).
1 finding from 1 review
Intervention not reported
Myocardial infarction at maximum · patients without heart failure
The intervention probably leads to lower myocardial infarction at maximum (moderate certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review